$6.62
6.10% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock price

$7.05
+1.13 19.09% 1M
-2.87 28.93% 6M
-0.68 8.80% YTD
-13.24 65.25% 1Y
-27.99 79.88% 3Y
-22.38 76.04% 5Y
-23.40 76.85% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.29 4.29%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $353.11m
Enterprise Value $260.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.12
P/S ratio (TTM) P/S ratio 4.24
P/B ratio (TTM) P/B ratio 1.35
Revenue growth (TTM) Revenue growth -7.66%
Revenue (TTM) Revenue $83.33m
EBIT (operating result TTM) EBIT $-231.25m
Free Cash Flow (TTM) Free Cash Flow $-175.56m
Cash position $234.69m
EPS (TTM) EPS $-4.64
P/E forward negative
P/S forward 1.13
EV/Sales forward 0.83
Short interest 15.74%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a REGENXBIO, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
92%
Hold
8%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
83 83
8% 8%
100%
- Direct Costs 50 50
9% 9%
60%
34 34
6% 6%
40%
- Selling and Administrative Expenses 56 56
21% 21%
68%
- Research and Development Expense 192 192
11% 11%
231%
-215 -215
14% 14%
-258%
- Depreciation and Amortization 16 16
6% 6%
19%
EBIT (Operating Income) EBIT -231 -231
14% 14%
-278%
Net Profit -227 -227
14% 14%
-273%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Positive
Seeking Alpha
8 days ago
Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M f...
Neutral
PRNewsWire
15 days ago
Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% compared to control With a differentiated novel construct and proactive short course immune modulation regimen, RGX-202 continues to demonstrate encouraging safety profile with no SAEs or AESIs Phase I...
Neutral
Seeking Alpha
21 days ago
REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Mitch Chan - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley Gena Wang - Barclays Annabel Samimy - Stifel Brian Skorney -...
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 353
Founded 2008
Website www.regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today